A randomized-controlled trial to investigate the effects of rivoglitazone, a novel PPAR gamma agonist on glucose-lipid control in type 2 diabetes

Thiazolidinedione Drugs and Cardiovascular Risks

(2010) Sanjay Kaul et al.   CIRCULATION

Associations of Hyperglycemia and Insulin Usage With the Risk of Cancer in Type 2 Diabetes: The Hong Kong Diabetes Registry

(2010) X. Yang et al.   DIABETES

The rise and fall of rosiglitazone

(2010) S. E. Nissen   EUROPEAN HEART JOURNAL

Development and validation of equations estimating glomerular filtration rates in Chinese patients with type 2 diabetes

(2010) Tak-Kei Leung et al.   KIDNEY INTERNATIONAL

Diabetes in Asia

(2009) Juliana C. N. Chan et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Potent Antidiabetic Effects of Rivoglitazone, a Novel Peroxisome Proliferator–Activated Receptor-γ Agonist, in Obese Diabetic Rodent Models

(2009) Shoichi Kanda et al.   JOURNAL OF PHARMACOLOGICAL SCIENCES

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial

(2009) Philip D Home et al.   LANCET

Rosiglitazone and Risk of Cancer: A meta-analysis of randomized clinical trials

(2008) M. Monami et al.   DIABETES CARE

Model-Based Development of a PPARγ Agonist, Rivoglitazone, to Aid Dose Selection and Optimize Clinical Trial Designs

(2008) Shashank Rohatagi et al.   JOURNAL OF CLINICAL PHARMACOLOGY